Market Closed

MLTX
MoonLake Immunotherapeutics
$ 12.50
-2.87%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated a day ago

MoonLake Immunotherapeutics News

Latest MoonLake Immunotherapeutics Stock News & MLTX Headlines

MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update
11 days ago | globenewswire.com
What's Going On with MoonLake Immunotherapeutics Stock on Thursday?
23 days ago | benzinga.com
MoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical Supremacy
2 months ago | seekingalpha.com
MoonLake Immunotherapeutics Target of Unusually High Options Trading (NASDAQ:MLTX)
3 months ago | defenseworld.net
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial
3 months ago | reuters.com
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
3 months ago | globenewswire.com
Arrowstreet Capital Limited Partnership Acquires New Shares in MoonLake Immunotherapeutics $MLTX
3 months ago | defenseworld.net
Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?
3 months ago | zacks.com
MoonLake Immunotherapeutics' CFO Sells 39K Shares
4 months ago | fool.com
MoonLake: 'Buy' Sonelokimab BLA Submission HS September And Label Expansion
5 months ago | seekingalpha.com
Load More

Download App

Keep track of your holdings and explore over 40,000 cryptocurrencies

oinCodex Android App
CoinCodex Mobile App
Market Closed

MLTX
MoonLake Immunotherapeutics
$ 12.50
-2.87%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated a day ago